MOLECULAR EXPRESS, INC
Doing business as MOLECULAR EXPRESS INC
- RANCHO DOMINGUEZ, CA 90220-5610
- molecularexpress.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
- Small Disadvantaged Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
MOLECULAR EXPRESS, INC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About MOLECULAR EXPRESS, INC
- Headquarters
- RANCHO DOMINGUEZ, CA 90220-5610
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIR1JMHFESEKD5
- CAGE337D8
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 56 awards
- Total awarded
- $36,987,550
- By phase
- SBIR Phase I: 38
- SBIR Phase II: 12
- STTR Phase I: 5
- STTR Phase II: 1
- By agency
- Department of Health and Human Services: 54
- Department of Defense: 2
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2024: 3
- 2023: 1
- 2022: 4
- 2021: 3
- 2020: 2
- 2019: 1
- 2018: 1
- 2017: 2
- 2016: 2
- 2015: 5
- 2014: 1
- 2013: 2
- 2012: 3
- 2011: 2
- 2009: 1
- 2008: 5
- 2007: 3
- 2006: 3
- 2005: 3
- 2004: 1
- 2003: 2
- 2002: 1
- 2001: 1
- 2000: 1
- 1999: 1
- 1998: 2
Awards (most recent first)
Preclinical Development of a ME-1001, a Synthetic Lung Surfactant
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $1,999,637
May 15, 2024 – Apr 30, 2026
Solicitation PA23-230 (2023) · Topic NHLBI
Development of a VesiVax TLR7 Formula as an Effective Adjuvant
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $2,999,352
- Direct to Phase II
Solicitation PHS-2024-1 (2024) · Topic 128
DESIGN AND ENGINEERING OF VESIVAX HIV IMMUNOGEN FORMULATIONS
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $1,999,866
Solicitation PHS-2020-1 (2020) · Topic 77
DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151.
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $599,925
Solicitation PHS-2023-1 (2023) · Topic 116
Niclosamide Formulations for the Treatment of Influenza Infections
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $298,479
Jul 8, 2022 – Jun 30, 2023
Solicitation PA20-260 (2020) · Topic NIAID
VesiVax Vaccine Formulation Against Neisseria gonorrhoeae
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $599,596
Feb 18, 2022 – Jan 31, 2024
Solicitation PA20-260 (2020) · Topic NIAID
Development of a VesiVax HIV Vaccine Formulation
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $1,994,571
Solicitation PHS-2021-1 (2020) · Topic 89
VesiVax HIVgp41e Vaccine Design
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $300,000
Solicitation PHS-2022-1 (2021) · Topic 101
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $2,169,278
Jun 18, 2021 – May 31, 2023
- Direct to Phase II
Solicitation PA20-260 (2020) · Topic NHLBI
THE CONTRACTOR SHALL TO EVALUATE THE DIFFERENT CO-DELIVERY METHODS OF A MODEL HIV ANTIGEN USING THE VESIVAX LIPOSOMAL PLATFORM.
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $299,994
Solicitation PHS2020-1 (2019) · Topic 76
DEVELOPMENT OF A VESIVAS IMMUNOSIMILAR FORMULATION
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $569,807
Solicitation PHS2021-1 (2020) · Topic 93
THE OBJECTIVE OF THIS CONTRACT IS TO IDENTIFY A POTENTIAL HIV ANTIGEN-CONJUGATED VACCINE FORMULATION BY EXPLORING CO-DELIVERY OF HIV ANTIGENS AND ADJU
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $299,961
Solicitation year 2019 · Topic 76
THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A VESIVAX PLATFORM-BASED LIPOSOMAL FORMULATION THAT WILL EFFICIENTLY DISPLAY THE HIV IMMUNOGEN.
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $299,993
Solicitation year 2019 · Topic 77
Evaluation of VesiVax Adjuvant Formulations for HIV Vaccines
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $599,983
Solicitation year 2018 · Topic NIAID
Contract Award for SBIR Topic 061 ""Mucosal Stimulatory VesiVax Vaccines Against Enteric Infections""
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $213,800
Solicitation year 2017 · Topic NIAID
Development of a Vaccine for the Prevention of Pulmonary Aspergillosis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $1,431,794
Jul 1, 2017 – Jun 30, 2019
Solicitation PA16-302 (2016) · Topic R
VesiVax Peanut Allergy Immunotherapy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $300,000
Feb 7, 2017 – Jan 31, 2019
Solicitation PA16-302 (2016) · Topic NIAID
The VesiVax System Vaccine Development Made Easy
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2016 · $1,499,000
Aug 1, 2016 – Jul 31, 2018
Solicitation PA15-269 (2015) · Topic NIAID
Optimization of VesiVax® Lipidated Tucaresol Formulations
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $225,000
Apr 1, 2016 – Mar 31, 2018
Solicitation PA15-269 (2015) · Topic NIAID
Development of a Gene and Oligonucleotide Delivery System
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $322,946
Sep 1, 2015 – Aug 31, 2016
Solicitation PA14-308 (2016) · Topic NCATS · Research partner: UNIVERSITY OF CALIFORNIA LOS ANGELES
Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2015 · $320,176
Sep 1, 2015 – May 31, 2017
Solicitation PA14-077 (2017) · Topic R42
Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $225,033
Sep 1, 2015 – Aug 31, 2016
Solicitation PA14-072 (2015) · Topic R42 · Research partner: SCRIPPS RESEARCH INSTITUTE
Development of a Vaccine for the Prevention of Pulmonary Aspergillosis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $329,911
Jun 15, 2015 – May 31, 2016
Solicitation PA14-071 (2015) · Topic NIAID
Design and Engineering of Nanoparticulate Universal Vaccines
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $290,263
Jun 15, 2015 – May 31, 2016
Solicitation PA14-071 (2015) · Topic NIAID
Engineering of a Novel CDN Nanoparticle Platform
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $245,943
Solicitation PA13-234 (2014) · Topic NIAID · Research partner: Stub
Showing the 25 most recent of 56 awards.
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard
- 541713Research and Development in NanotechnologySmall business under this code’s size standard
SAM.gov reports this entity as small under 2 of 2 NAICS codes. Size is determined per code (SBA size standards).
Socio-economic status
Learn more about small business set-asidesProduct & service codes (PSC)
- AJ11GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH
- AJ12GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; APPLIED RESEARCH
- AJ13GENERAL SCIENCE & TECHNOLOGY R&D SVCS; GENERAL SCIENCE & TECHNOLOGY; EXPERIMENTAL DEVELOPMENT
PSC names from the Acquisition.gov PSC Manual (opens in a new tab) (April 2025 edition), checked Nov 12, 2026.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with MOLECULAR EXPRESS, INC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.